Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer

Table 2 Prognosis analysis of recurrence-free survival and overall survival of total patients (n = 366)

Characteristics	RFS		OS
	HR (95% CI)	P value	HR (95% CI)	P value
Age (yr)
≤ 60
> 60	1.12 (0.80-1.57)	0.488	1.16 (0.83-1.64)	0.373
Gender
M
F	1.18 (0.85-1.65)	0.315	1.09 (0.78-1.53)	0.600
PKM2
Negative
Positive	0.93 (0.66-1.32)	0.713	0.92 (0.65-1.30)	0.637
T stage
T1/2/3
T4	6.12 (4.25-8.81)	< 0.001	5.04 (3.51-7.22)	< 0.001
N stage
N0/1/2
N3	6.02 (4.29-8.46)	< 0.001	5.64 (4.01-7.95)	< 0.001
Stage
I/II
III	8.42 (5.48-12.94)	< 0.001	6.70 (4.41-10.16)	< 0.001

RFS: Recurrence-free survival; OS: Overall survival; HR: Hazard ratio; PKM2: The M2 isoform of pyruvate kinase; T: Tumor; N: Node; 95% CI: 95% confidence interval.